

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Evaluation of Parent and Youth Experiences in Advisory Groups as part of a Mental Health Care Clinical Trial: Protocol for a Mixed Method Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059689
Article Type:	Protocol
Date Submitted by the Author:	29-Nov-2021
Complete List of Authors:	<p>Rasiah, Jananee; Athabasca University Faculty of Health Disciplines, ; University of Alberta, Freedman, Stephen; University of Calgary, Departments of Pediatrics, Emergency Medicine and Community Health Sciences; The Hospital for Sick Children, Pediatrics Macdonald, Lee ; Alberta Health Services, Planning and Performance Prisnie, Kass; University of Calgary Cumming School of Medicine, Pediatrics Eltorki, Mohamed; McMaster University Faculty of Health Sciences, Pediatrics Finkelstein, Yaron; University of Alberta, Department of Medicine; University of Alberta, Department of Pediatrics Hopkin, Gareth ; Institute of Health Economics Santana, Maria-Jose; University of Calgary, Community Health Sciences Thull-Freedman, Jennifer ; University of Calgary Cumming School of Medicine, Departments of Pediatrics and Emergency Medicine Stang, Antonia; University of Calgary, Pediatrics; Alberta Children's Hospital, Pediatrics Prebeg, Matthew; Centre for Addiction and Mental Health, Gagnon, Isabelle; McGill University, School of Physical and Occupational Therapy; Montreal Children's Hospital of the McGill University Health Center, Trauma Steele, Margaret; Memorial University of Newfoundland, Discipline of Psychiatry, Faculty of Medicine Mater, Ahmed; University of Saskatchewan, Pediatrics Katz, Laurence; University of Manitoba, Department of Psychiatry, Rady Faculty of Health Sciences Greenfield, Brian; McGill University, Psychiatry Plotnick, Laurie; McGill University, Pediatrics Monga, Suneeta; The Hospital for Sick Children, Dept. of Psychiatry Lipman, Ellen; McMaster University, Psychiatry and Behavioural Neurosciences Wright, Bruce; University of Alberta Faculty of Medicine and Dentistry, Pediatrics; Alberta Health Services, Stollery Children's Hospital Dimitropoulos, Gina; University of Calgary, Porter, Robert; Memorial University of Newfoundland, Pediatrics, Faculty of Medicine Hurley, Katrina; Dalhousie University Faculty of Medicine, Emergency Medicine</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Al Hamarneh, Yazid; University of Alberta, Medicine Newton, Amanda; University of Alberta,
Keywords:	HEALTH SERVICES ADMINISTRATION & MANAGEMENT, MENTAL HEALTH, ACCIDENT & EMERGENCY MEDICINE



1
2
3 **Title: Evaluation of Parent and Youth Experiences in Advisory Groups as part of a Mental**
4 **Health Care Clinical Trial: Protocol for a Mixed Method Study**
5
6
7
8
9

10 **Authors**

11
12 Jananee Rasiah
13 jrasiah@athabascau.ca
14 Athabasca University, Faculty of Health Disciplines, Athabasca, AB
15
16

17 Stephen B. Freedman
18 stephen.freedman@albertahealthservices.ca
19 University of Calgary, Departments of Pediatrics,
20 Emergency Medicine and Community Health Sciences, Calgary, AB
21
22

23 Lee Macdonald
24 Lee.Macdonald@albertahealthservices.ca
25 Alberta Health Services, Planning and Performance, Edmonton, AB
26
27

28 Kassi Prisnie
29 Kassi.Prisnie@albertahealthservices.ca
30 University of Calgary Cumming School of Medicine, Pediatrics, Calgary, AB
31
32

33 Mohamed Eltorki
34 eltorkim@mcmaster.ca
35 McMaster University, Faculty of Health Sciences
36 Department of Pediatrics, Division of Pediatric Emergency Medicine, Hamilton, ON
37
38

39 Yaron Finkelstein, MD,
40 Yaron.Finkelstein@sickkids.ca
41 Divisions of Emergency Medicine and Clinical Pharmacology and Toxicology,
42 Hospital for Sick Children, University of Toronto, Toronto, ON
43
44

45 Gareth Hopkin
46 gareth.hopkin@wales.nhs.uk
47 Institute of Health Economics, Edmonton, AB
48 Velindre University NHS Trust, Cardiff, Wales
49
50

51 Maria J. Santana
52 mjsantan@ucalgary.ca
53 University of Calgary, University of Calgary, Community Health Sciences, Calgary, AB
54
55
56
57
58
59
60

1
2
3 Jennifer Thull-Freedman
4 Jennifer.thull-freedman@ahs.ca
5 University of Calgary Cumming School of Medicine, Departments of Pediatrics and Emergency
6 Medicine, Calgary, AB
7

8
9 Antonia S. Stang
10 Antonia.Stang@albertahealthservices.ca
11 Departments of Pediatrics, Emergency Medicine and Community Health Sciences,
12 University of Calgary, Calgary, AB
13

14
15 Matthew Prebeg (CAMH)
16 matthew.prebeg@camh.ca
17 Centre for Addiction and Mental Health, Toronto ON
18

19
20 Isabelle Gagnon
21 Isabelle.gagnon8@mcgill.ca
22 School of Physical & Occupational Therapy and Department of Pediatrics, Faculty of Medicine
23 and Health Sciences, McGill University, Montreal, QC
24

25
26 Margaret Steele
27 DeanofMedicine@med.mun.ca
28 Discipline of Psychiatry, Faculty of Medicine, Memorial University of Newfoundland,
29 St. John's NL
30

31
32 Ahmed Mater
33 mater999@me.com
34 College of Medicine, University of Saskatchewan, Saskatoon, SK
35

36
37 Laurence Katz
38 LKatz@hsc.mb.ca
39 Department of Psychiatry, Rady Faculty of Health Sciences, Winnipeg, MB
40

41
42 Brian Greenfield
43 briangreenfield13@gmail.com
44 Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, QC
45

46
47 Laurie H. Plotnick
48 laurie.plotnick@mcgill.ca
49 Department of Pediatrics, Faculty of Medicine and Health Sciences, McGill University,
50 Montreal, QC
51

52
53 Suneeta Monga
54 suneeta.monga@sickkids.ca
55 Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, ON
56
57
58
59
60

1
2
3
4 Ellen Lipman
5 lipmane@mcmaster.ca
6 Department of Psychiatry and Behavioural Neurosciences, Faculty of Health Sciences,
7 McMaster University, Hamilton, ON
8
9

10 Bruce Wright
11 bruce.wright2@albertahealthservices.ca
12 Department of Pediatrics, Faculty of Medicine and Dentistry,
13 University of Alberta, Edmonton, AB
14

15
16 Gina Dimitropoulos
17 gdimit@ucalgary.ca
18 Faculty of Social Work, University of Calgary, Calgary, AB
19

20 Robert Porter
21 bobsterpot@gmail.com
22 Discipline of Pediatrics, Faculty of Medicine, Memorial University of Newfoundland, St. John's
23 NL
24
25

26 Katrina Hurley
27 Katrina.Hurley@iwbk.nshealth.ca
28 Division of Pediatric Emergency Medicine, Department of Emergency Medicine, Faculty of
29 Medicine, Dalhousie University, Halifax, NS
30

31
32 Yazid Al Hamarneh
33 Scientific Officer, EPICORE Centre, Department of Medicine, University of Alberta, Edmonton,
34 AB
35

36 Amanda S. Newton
37 mandi.newton@ualberta.ca
38 Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton,
39 AB
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Patient engagement in health care research is a necessity to ensure that research objectives align with priorities, outcomes, and needs of the population under study, and to facilitate ease of implementation and adoption of findings. In clinical trials, there is an increasing focus on patient engagement during the planning and conduct of clinical trials due to the potential for ethical and methodological benefits. As patient engagement in clinical trials increases, there is a need to evaluate the approaches of these activities to contribute evidence on what is most appropriate and successful. The purpose of this study is to evaluate patient engagement processes and the activities of patient partners during and after a pediatric mental health care trial.

Methods and analysis: Using a mixed-methods study design, we will evaluate patient partners' engagement activities across set time points during the trial and after trial completion. In this study, the term "patient partner" is inclusive of two groups of people with lived experience: (1) caregivers (parents, formal/informal caregivers, and family), and (2) youth (ages 15-24 years). Engagement will be measured using the participant and project questionnaires of the Public and Patient Engagement Evaluation Tool (PPEET), followed sequentially by semi-structured interviews. Quantitative data from the PPEET questionnaire will be analyzed and reported using descriptive statistics. Data from open-ended questions from the PPEET questionnaires and semi-structured interviews will be analyzed using thematic analysis.

Ethics and dissemination: Approval from Athabasca University Research Ethics Board will be obtained for this project. Findings will be disseminated at both academic and public venues in-person and online using platforms that are caregiver and youth friendly.

Strengths and limitations of this study

- Patient engagement activities will be widely applicable to other pediatric clinical trials
- Evaluation findings will inform future patient engagement plans for pediatric clinical trials
- Potential to advance the science of patient engagement in research as a whole
- Given the length of the trial, we may encounter challenges with sustained parent and youth engagement over the course of the trial

Introduction

Within the last decade, research funding organizations in the United Kingdom, United States, Canada, Australia, and New Zealand have required that patient engagement be an integral part of the design, conduct, dissemination, and implementation of findings emerging from social and health care research (1-5). Patient engagement occurs when patients become partners through meaningful and active collaboration across the research process (2, 6). A recent systematic review has reported ethical, methodological, and study quality benefits from engaging patients as partners in health research (6). These benefits have also been demonstrated through youth engagement in research, in particular, in the areas of health promotion (7), mental health (8, 9), chronic pain (10), and community development (11). When youth have been engaged in research, the results have also been more likely to be implemented and adopted widely (12, 13).

There is the emerging evidence around the benefits to engage patients as partners in clinical trials aimed to evaluate non-pharmacological or pharmacological interventions (14-17). These benefits include: (i) more appropriate and sensitive/ethical research designs; (ii) more appropriate wording and timing of administration of research instruments and interventions; (iii) improved readability and accessibility of research materials (*ethical benefits*); (iv) more patient and/or caregiver relevant research outcomes or endpoints (*methodological benefits*); (v) improved recruitment, retention, diversity, and trial experience/satisfaction of study participants; (vi) better adherence to the trial protocol; and (vii) faster study completion (*study quality benefits*) (17). Given this evidence, we saw the benefits of prioritizing engagement with patients as partners across the lifespan of our pediatric mental health care trial.

Overview: Mental Health Care Pediatric Clinical Trial

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Trial development began in 2018, when members of our research team alongside a group of patients, families, and health care providers identified the need to make improvements to pediatric mental health care in emergency departments (EDs) (18). This group recognized EDs as a vital clinical care setting for children and youth experiencing acute mental health or substance misuse crises (19). Such crises were acknowledged to be stressful and overwhelming, leaving the youth and family vulnerable in the absence of appropriate care. The team reinforced the position that ED-based care should be: (1) family centred and multidisciplinary, (2) informed by evidence-based approaches that identify risk, inform ED care and disposition decision-making, and (3) consider family needs and preferences (19, 20). In response to this position, a novel ‘bundle’ of mental health care was created with feedback from patient partners. The bundle combines three evidence-based approaches to ED care, as follows:

1. Ask Suicide-Screening Questions (ASQ) to identify suicide risk at ED triage and to facilitate faster access to appropriate treatment pathways (21-23);
2. HEADS-ED, a clinical mnemonic (Home, Education, Activities/peers, Drug/alcohol, Suicidality, Emotions and behaviour, Discharge Resources), for a focused mental health psychosocial evaluation to guide ED care and disposition decision-making (20, 24); and
3. A ‘Choice’ appointment post-ED care, in accordance with the Choice And Partnership Approach (CAPA) to care. This is a family-centred approach to mental health service organization (25), and its use recognizes the value of connecting children and youth to follow-up services after a crisis.

The bundle will be evaluated using a type 1 comparative effectiveness-implementation hybrid design (26). A cluster randomized trial will evaluate the effectiveness of the bundle compared to current standards of ED mental health care, while bundle implementation will be

1
2
3 evaluated using multi-methods to better understand barriers and facilitators to the adoption in ED
4 care. The trial will take place in eight pediatric EDs across Canada in partnership with Pediatric
5 Emergency Research Canada (PERC), a national research network. The Conjoint Health
6 Research Ethics Board (CHREB), University of Calgary approved this study effective January 4,
7 2021 (Reference ID: REB20-1825). This trial was registered at clinicaltrials.gov (Identifier:
8 NCT04902391) with an estimated start date of November 1, 2021 and completion date of August
9 1, 2025. The protocol for this trial was submitted elsewhere for publication.

10
11 A patient engagement plan was created for the trial that was informed by principles of
12 patient engagement from many sources, including those specific to youth and caregivers (2, 27-
13 31). The plan will be evaluated in a trial sub-study that aims to evaluate the engagement of youth
14 and caregivers in the design and conduct of the trial as well as research team member
15 involvement in patient engagement.

16 17 **Patient and Public Involvement**

18
19 The study protocol was conceptualized by JR (lead for patient engagement sub-study)
20 with support from ASN (co-principal investigator of the primary mental health care pediatric
21 trial). LM (caregiver lead) and MP (youth lead) with lived experience reviewed and provided
22 feedback on this study protocol. According to the patient engagement plan described below, all
23 caregiver and youth advisory members, will be invited to provide feedback on both process and
24 findings at different time-points across the primary mental health care pediatric trial. For the
25 patient engagement evaluation study described below, caregiver and youth advisory group
26 members will be invited to partake in the interpretation of the aggregate results, editing, and
27 preparation of the manuscript for publication. Caregiver and youth advisory group members will
28 be invited to contribute to the overall knowledge integration and dissemination plan. Both patient
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 partner contributors (LM and MP) met the ICMJE criteria for authorship and as such we
4
5 acknowledge their valuable contributions through coauthorship of this study protocol.
6

7
8 Engagement of patient partners has ensured further accuracy, readability, and relevance of this
9
10 protocol to the science and practice of patient engagement in pediatric clinical trials.
11

12 **Patient Engagement Plan**

13 **Overview**

14
15 The patient engagement plan has two foci: (i) consultation in trial planning, whereby
16
17 youth and caregivers had the opportunity as advisors to provide feedback on the trial design, and
18
19 (ii) partnership, whereby youth and caregivers will be partners alongside research team members
20
21 during trial conduct, with both groups actively involved in collaborating and leading trial related
22
23 activities. These foci align with the practices recommended by the Canadian Institute of Health
24
25 Research when developing partnerships between patients and researchers (33). We will use the
26
27 term ‘patient advisor’ to denote those who are involved in a one-time engagement activity versus
28
29 ‘patient partner’ who will provide feedback during patient engagement activities throughout the
30
31 lifespan of the trial.
32
33
34
35
36

37 **Participants and Recruitment**

38
39 We used a multi-pronged approach to recruit patient partners representing two groups of
40
41 people with lived experience: (1) caregivers (parents, formal/informal caregivers, and family)
42
43 and (2) youth (ages 15-24 years). We will specify the group we refer to within the protocol for
44
45 particular instances as needed, but otherwise we mean both groups. Initial recruitment began in
46
47 2018 with youth and caregivers from two family advisory councils for child and adolescent
48
49 mental health services in Calgary and Edmonton, Alberta, Canada invited to provide feedback
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and perspectives on bundle design and trial planning. The participation of these advisors has
4
5 concluded, with one partner staying as a team member for the trial.
6
7

8 The next phase of recruitment will focus on the participation of youth in a Youth
9
10 Advisory Group and caregivers in a Caregiver Advisory Group; the groups will be active during
11
12 trial conduct and post-trial knowledge translation activities. During youth and caregiver
13
14 recruitment, we will prioritize equity, diversity, and inclusion-based practices in patient
15
16 engagement (32), and plan to recruit individuals from different demographic groups, based on
17
18 age, gender identity, cultural identity, disability, or education. We will set up two advisory
19
20 groups to minimize power differentials amongst youth and caregivers and foster a safe space
21
22 whereby all members are comfortable sharing their perspectives.
23
24
25

26 Youth engagement liaisons/coordinators from the Centre for Addiction and Mental
27
28 Health (<https://www.camh.ca/>) (led by MP) will assist with recruitment of youth to join the
29
30 Youth Advisory Group. Caregiver recruitment will be overseen by another team member (JL)
31
32 who will use convenience sampling to recruit individuals through organizations partnered with
33
34 the team (Canadian Mental Health Association, Translating Emergency Knowledge for Kids
35
36 [TREKK], Children's Healthcare Canada).
37
38
39

40 Youth and caregivers who indicate interest in participating will be invited to attend a
41
42 virtual introductory meeting (one for youth; one for caregivers) with the trial co-leads (SBF and
43
44 ASN) and patient engagement leads (JR, MP, and LM). The meeting will provide an opportunity
45
46 for individuals to learn about the trial and the goal of patient partner engagement. Those
47
48 interested in joining the team as advisory group members will be asked to contact the trial's
49
50 patient engagement evaluation study lead (JR) and youth engagement lead (MP) to further
51
52 discuss and confirm their interest. Informed consent will be obtained at that time. Patient partners
53
54
55
56
57
58
59
60

1
2
3 can voluntarily revoke consent at any time during the course of the trial. The goal is to have
4 membership in both advisory groups filled between November 2021 and January 2022; the trial
5
6 begins February 2022.
7
8

9 10 **Sample Size**

11
12 We could not find evidence in the literature to support best practice for optimal group
13 size for patient engagement in research. Therefore, we will exercise pragmatic considerations
14 and recommendations from team members and project liaisons with extensive experience
15 working in patient engagement. In particular, the size of the group should foster meaningful
16 engagement, so that we are able to have robust discussion, and patient partners can share ideas in
17 a safe space. Conversely, we do not want a group too large that it is ineffective to engage
18 partners in discussions. We anticipate a target size of five to ten patient partners per advisory
19 group will be sufficient to lead to a meaningful discussion.
20
21
22
23
24
25
26
27
28
29

30
31 Patient partners that do not continue for the full duration of planned patient engagement
32 activities will be included in the sample if they are willing. Patient partners who attend the
33 virtual introductory meeting with the study co-lead, but later decline to participate in an advisory
34 group will be asked if they are willing to share confidentially the reasons that led to the decision
35 to forego participation. If we have attrition of advisory group members at any stage of the
36 engagement process, we want to have the opportunity to formally document their reasons that led
37 to that decision as part of the evaluation of patient engagement.
38
39
40
41
42
43
44
45

46 47 **Advisory Group Activities**

48
49 Advisory groups will be co-chaired by (MP, LM, and JR). At the first meeting of each
50 group, members will discuss group norms, establish terms of reference for the respective
51 advisory groups, including role description, individual goals as they relate to the patient
52
53
54
55
56
57
58
59

1
2
3 engagement activities, frequency of meetings, compensation, and platforms to exchange and
4
5 share information about the study. Patient partners will have the ability to choose the types of
6
7 engagement activities that they would like to participate in, and this will be determined on an
8
9 individual and/or advisory group basis. These activities include co-leading the advisory group
10
11 alongside the chairs, providing feedback on recruitment materials for the trial and telephone
12
13 scripts used during data collection with trial participants, informing changes to recruitment and
14
15 retention processes during trial conduct, providing impressions on the results, and
16
17 designing/preparing materials to disseminate trial results (e.g., statements for social media use,
18
19 infographics for families). Patient partners will also have the opportunity to apply for funding to
20
21 attend conferences and courses related to children's mental health (budgeted within the trial)
22
23 and/or work with the patient engagement evaluation study lead (JR) to plan and conduct
24
25 evaluation meetings.
26
27
28
29

30 **Patient Engagement Evaluation Study**

31 **Design**

32
33 We are using a mixed-method design to evaluate the trial's patient engagement plan (34,
34
35 35). This will involve surveying patient advisors and partners as well as research team members
36
37 on engagement experiences followed by semi-structured interviews of patient partners to gather
38
39 more detailed information on engagement experiences and activities highlighted in survey
40
41 responses. We will use the Good Reporting of Mixed Method Study Criteria (38) and the
42
43 Guidance for Reporting Involvement of Patients and the Public (GRIPP2) (39) to assess the
44
45 quality of reporting of our mixed method patient engagement evaluation study procedures and
46
47 findings.
48
49
50
51
52

53 **Framework for Measuring Patient Engagement**

We are using a framework to guide outcome measurement. This framework contains four domains—integrity of design and process; flexibility; mentorship; influence and impact—and was adapted from the published literature on patient and youth engagement (31, 40). Integrity of design and process will be assessed by examining advisory group representation (e.g., Do members represent different experiences based on age, gender identity, cultural identity, disability, or education?) and how group members are supported in patient engagement activities (e.g., Are members compensated for their involvement in activities? Is information produced at an appropriate education level for members?) (31). Flexibility of advisory groups with caregivers and youth will be assessed by examining the terms of reference (role, structure, norms, and frequency of interactions) of the groups and how those terms of reference are carried out across the research project (40). Mentorship will be assessed by asking patient partners about advisory group trial activities and opportunities that aligned with personal goals (40). Influence and impact will be assessed by examining whether patient engagement activities informed or changed trial decisions (31).

Measurement of Patient Engagement

Public and Patient Engagement Evaluation Tool

We will use the Public and Patient Engagement Evaluation Tool (PPEET) to measure patient engagement across our domains of interest: integrity of design and process, flexibility, mentorship, and influence and impact. The PPEET is comprised of two questionnaires which will allow us to evaluate perspectives and experiences of advisory group members (participant questionnaire) and research team members (project questionnaire). The participant questionnaire also contains questions to measure one-time and ongoing patient engagement experiences, which will ensure that patient partners with different experiences contribute to the evaluation. At this

1
2
3 time, we are aware of at least twenty-seven tools to evaluate patient and public engagement (1,
4 36, 37). We chose the PPEET because it was used to evaluate patient and public engagement
5 within the context of health research, and the tool was highly rated by the Centre of Excellence
6 on Partnership with Patients and the Public (CEPPP) (1, 36, 37).
7
8
9

10
11 In Table 1, we outline how our domains of interest will be measured using the PPEET
12 participant and project questionnaires. We also identify time-points of when each questionnaire
13 will be administered. Advisory group members will also be asked to fill out a six-item
14 demographic questionnaire, as part of the PPEET, to provide to allow us to measure
15 representation as part of integrity of design and process. The questions include year of birth, sex,
16 group of people or communities one identifies with, highest level of education completed,
17 current work status, and paid experience in a health care profession.
18
19
20
21
22
23
24
25
26
27

28 **PPEET Participant Questionnaire**

29
30 The one-time engagement questionnaire is comprised of 19 questions: 13 questions based
31 on a five-point Likert scale (range: strongly disagree to strongly agree) and six open-ended
32 questions. The questionnaire will be administered to each patient advisor immediately after the
33 conclusion of an engagement activity. The on-going engagement questionnaire will be
34 administered to patient partners every three to six months during trial conduct. This
35 questionnaire is comprised of a total of 20 questions: 14 questions based on a five-point Likert
36 scale (range: strongly disagree to strongly agree) and six open-ended questions.
37
38
39
40
41
42
43
44
45
46

47 **PPEET Project Questionnaire**

48
49 We will use the PPEET three-module project questionnaire to assess involvement in
50 patient engagement among the principal investigators, project manager, implementation site
51 leads, and youth engagement liaisons/coordinators. The first module (Module A) consists of 12
52
53
54
55
56
57
58
59
60

1
2
3 questions on a five-point Likert scale (range: strongly disagree to strongly agree) and three open-
4 ended questions to assess how and whether study team members have chosen appropriate patient
5 engagement activities during the planning stage. This module will be administered prior to trial
6 conduct and after the run-in period. The second module (Module B) identifies how well patient
7 engagement activities were executed (10 five-point Likert questions; six open-ended questions)
8 and will be administered after the trial engagement activities are completed. The third module
9 (Module C) will evaluate the impact of patient engagement activities. This module includes four
10 questions (five-point Likert scale; range: strongly disagree to strongly agree) and four open-
11 ended questions, that will be administered three to six months after the completion of the
12 engagement activities.
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **Semi-Structured Interviews**

27
28 We will interview patient partners at the end of the trial after the completion of all
29 engagement activities. Interview questions will be developed based on the themes that emerge
30 from the open-ended responses collected at different time-point using the PPEET with the intent
31 to gather more information on engagement experiences and activities (43). Patient partners will
32 be offered the choice to participate in individual or focus group interviews. Focus group
33 interviews will be held separately for youth and caregivers. A final forum inviting all patient
34 partners and research team members to attend will be held to discuss and obtain feedback on
35 synthesized questionnaire results and interview findings.
36
37
38
39
40
41
42
43
44
45
46

47 **Additional Data Sources: Supporting Documents and Trial Protocol Documents**

48
49 Supporting documents for the pediatric mental health care trial such as meeting agendas,
50 minutes, or tailored resources for advisory group members will be reviewed monthly and will
51 serve as additional data sources to understand patient engagement activities. Trial protocol
52
53
54
55
56
57
58
59
60

documents will be collected annually from the trial research coordinator to determine how feedback from advisory group members were used to inform/modify trial decisions.

Data Collection and Management

We will administer the PPEET online using the Research Electronic Data Capture (REDCap©) tools (44) hosted and supported by the Women and Children's Health Research Institute at the University of Alberta. Data collected through this platform will be de-identified and will not be tracked to any individual participant. In exceptional cases, such as limited participant access to online environments, the PPEET will be administered via telephone with answers entered by the interviewer into the REDCap© database. Data will be stored in REDCap© until exported for analysis.

Semi-structured interviews will be conducted via telephone/video-conferencing platform hosted by the University of Calgary (Zoom©) and the audio will be recorded. Interview recordings will be transcribed verbatim, checked for accuracy against the original recordings, and identifiers will be removed from the transcripts to maintain confidentiality. Data from the semi-structured interviews and the audio recordings will be stored securely in a server at the University of Alberta until the data are transcribed and subsequently analyzed.

Field notes will be kept when additional data sources are reviewed. Supporting documents will be reviewed during regular advisory group meetings to keep informed of the trial progress. Trial protocol documents will be collected and reviewed annually from the trial research coordinator to note modifications that have been implemented across sites based on advisory group members' feedback.

Table 1. Overview of the approach to measuring patient engagement.

Integrity of design and process; Flexibility; Mentorship		
PPEET questionnaire	Questionnaire outcomes	Administration time-point
Participant Questionnaire: One-time engagement activities (Module A – Parts A and B)	<ul style="list-style-type: none"> • Advisory group members represent diverse range of views • Advisory group members are provided supports that enable participation in engagement activities • Online platforms suitable for communication with patient partners • Clear and bi-directional communication achieved among patient partners and researchers • Mentorship opportunities created and tailored to patient partners' interests 	At the end of the activity on the same day
Participant Questionnaire: Ongoing engagement activities (Module B – Parts A and B)		Between 3-6 months
Project Questionnaire (Module A – Parts A, B, and C)		Pre-trial conduct (pre-recruitment of trial participants)
Influence and impact		
Participant Questionnaire: One-time engagement activities (Module A – Parts C and D)	<ul style="list-style-type: none"> • Engagement activities inform planning and/or decision making in the trial • Engagement activities improve patient partners' knowledge of mental health and substance use crises in emergency departments • Engagement activities improve patient partners' knowledge of the patient and family-centred acute mental health care bundle and need for implementation • Increased confidence and trust of patient partners in members of the team • Increased confidence of patient partners in the study purpose • Increased confidence of patient partners in the impact of bundle implementation on mental health 	At the end of the activity on the same day
Participant Questionnaire: Ongoing engagement activities (Module B – Parts C and D)		Between 3-6 months
Project Questionnaire (Module B – Parts A, B, and C)		Post-activity
Project Questionnaire (Module C – Parts A, B, and C)		3-6 months after engagement has concluded

Data Analysis

Data from the PPEET will be entered into SPSS© Version 27. We will use descriptive statistics (e.g., means and standard deviations, medians with interquartile range) to report group characteristics and responses to the Likert scale questions. Frequency and percentages will be reported for categorical information. Data from open-ended questions (45) and semi-structured interviews will be imported into NVIVO © Version 12. We will undertake thematic analysis (45) to analyze these data. Data from open-ended questions will be grouped by question and then coded for common themes that arise across the data. The primary coder (research nurse or graduate student) and first author (JR) will meet at least three times during the development and application of the coding scheme as part of an iterative process to ensure coding reliability. Coding reliability by the study co-lead (ASN) will be completed to resolve inconsistencies or disputes and to review independent coding of selected data excerpts.

Data from semi-structured interviews will be analyzed using the coding scheme as a guide. Data that cannot be coded to existing codes or themes will be noted. In the later stages of analysis, the study co-lead (ASN) will independently code data excerpts to maintain coding reliability. Advisory group members' feedback on supporting documents and trial protocol documents will be reviewed and synthesized into field notes by a research nurse and research assistant, which will be reported as a narrative.

Ethics and Dissemination

Ethical approval for this study was obtained through the Athabasca University Research Ethics Board (file no: 24575) for one year and is subject for renewal on an annual basis since the project is ongoing beyond one year. All participating advisory group members will receive an information sheet that will provide details on the purpose of the study, identify the potential

1
2
3 risks/benefits, and explain the voluntary nature of their participation. Patient advisors and
4 partners can revoke consent from participating in the parent or youth advisory group and
5 evaluation activities at any time. Patient advisors and partners may choose to omit particular
6 questions while filling out the survey or during the interview (pertains only to patient partners).
7
8 All data will be de-identified; therefore, individual participant data cannot be removed once
9 collected. Data will be kept confidential. All data will be stored using secured software on a
10 password-protected server and device.
11
12
13
14
15
16
17
18

19 Patient engagement evaluation findings will be shared with parent and youth advisory
20 group members during virtual meetings. Advisory group members will be asked about how the
21 results fit within the organizing framework and whether the patient engagement outcomes were
22 met. Dissemination of findings from this patient engagement evaluation study for the pediatric
23 mental health care trial will be in the form of an academic publication in a reputable peer-
24 reviewed journal, presentations at TREKK and PERC conferences/meetings, public presentations
25 at appropriate venues, and as posts or blogs on the research study website and online platforms
26 that are parent and youth friendly. Research team members and advisory group members will be
27 invited to co-author, co-develop, and co-present these findings targeted at multiple venues.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributorship statement:

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Competing interests: None declared.

Funding: This trial is funded by the Canadian Institutes of Health Research (CIHR) as a Strategy for Patient-Oriented Research (SPOR) Innovative Clinical Trial Multi-Year Grant (Funding reference number: MYG – 171686).

Data sharing statement: No, do not send my information to Dryad.

Ethics ID: Athabasca University Research Ethics Board review was approved effective November 25, 2021. Reference ID: 24575 (Project title: Evaluation of Parent and Youth Experiences in Advisory Groups as part of a Mental Health Care Clinical Trial: Protocol for a Mixed Method Study)

Ethics ID for primary trial: The Conjoint Health Research Ethics Board (CHREB), University of Calgary review (Primary Site) was approved effective January 4, 2021. Reference ID: REB20-1825 (Project title: A Multi-Disciplinary, Patient-Partnered, Pan-Canadian, Comparative Effectiveness Evaluation of an Innovative Acute Pediatric Mental Health and Addiction Care Bundle)

Trial registration ID: clinicaltrials.gov; ClinicalTrials.gov Identifier: NCT04902391

References

1. Boivin A, Richards T, Forsythe L, Grégoire A, L'Espérance A, Abelson J, et al. Evaluating patient and public involvement in research. *BMJ*. 2018;363:k5147.
2. Canadian Institutes of Health Research. Strategy for Patient Oriented Research. Patient engagement framework Ottawa: CIHR; 2014 [Available from: http://www.cihr-irsc.gc.ca/e/documents/spor_framework-en.pdf].
3. Frank L, Forsythe L, Ellis L, Schrandt S, Sheridan S, Gerson J, et al. Conceptual and practical foundations of patient engagement in research at the patient-centered outcomes research institute. *Qual Life Res*. 2015;24(5):1033-41.
4. Saunders C, Crossing S, Girgis A, Butow P, Penman A. Operationalising a model framework for consumer and community participation in health and medical research. *Aust New Zealand Health Policy*. 2007;4:13.
5. Staley K. *Exploring Impact: Public involvement in NHS, public health and social care research*. Eastleigh; 2009.
6. McCarron TL, Clement F, Rasiah J, Moran C, Moffat K, Gonzalez A, et al. Patients as partners in health research: A scoping review. *Health Expect*. 2021.
7. Peréa FC, Sayles NR, Reich AJ, Koomas A, McMann H, Sprague Martinez LS. "Mejorando Nuestras Oportunidades": Engaging Urban Youth in Environmental Health Assessment and Advocacy to Improve Health and Outdoor Play Spaces. *Int J Environ Res Public Health*. 2019;16(4).
8. Bell E. Young Persons in Research: A Call for the Engagement of Youth in Mental Health Research. *Am J Bioeth*. 2015;15(11):28-30.
9. Mawn L, Welsh P, Stain HJ, Windebank P. Youth Speak: increasing engagement of young people in mental health research. *J Ment Health*. 2015;24(5):271-5.
10. Birnie KA, Dib K, Ouellette C, Dib MA, Nelson K, Pahtayken D, et al. Partnering For Pain: A Priority Setting Partnership to identify patient-oriented research priorities for pediatric chronic pain in Canada *CMAJ*. 2019;7(4):E654-E64
11. Battaglia TA, Pamphile J, Bak S, Spencer N, Gunn C. Connecting Community to Research: A Training Program to Increase Community Engagement in Research. *Prog Community Health Partnersh*. 2019;13(2):209-17.
12. Checkoway B, Richards-Schuster K. Youth Participation in Community Evaluation Research. *American Journal of Evaluation*. 2003;24(1):21-33.
13. Hawke LD, Darnay K, Relihan J, Khaleghi-Moghaddam M, Barbic S, Lachance L, et al. Enhancing researcher capacity to engage youth in research: Researchers' engagement experiences, barriers and capacity development priorities. *Health Expect*. 2020;23(3):584-92.
14. Bartlett SJ, Barnes T, McIvor RA. Integrating patients into meaningful real-world research. *Ann Am Thorac Soc*. 2014;11 Suppl 2:S112-7.
15. Domecq JP, Prutsky G, Elraiyah T, Wang Z, Nabhan M, Shippee N, et al. Patient engagement in research: a systematic review. *BMC Health Serv Res*. 2014;14:89.
16. Bagley HJ, Short H, Harman NL, Hickey HR, Gamble CL, Woolfall K, et al. A patient and public involvement (PPI) toolkit for meaningful and flexible involvement in clinical trials – a work in progress. *Research Involvement and Engagement*. 2016;2(1):15.
17. Vat LE, Finlay T, Jan Schuitmaker-Warnaar T, Fahy N, Robinson P, Boudes M, et al. Evaluating the "return on patient engagement initiatives" in medicines research and development: A literature review. *Health Expect*. 2020;23(1):5-18.

18. Bialy L, Plint AC, Freedman SB, Johnson DW, Curran JA, Stang AS, et al. Pediatric Emergency Research Canada (PERC): Patient/Family-informed Research Priorities for Pediatric Emergency Medicine. *Academy of Emergency Medicine*. 2018;1365-74.
19. Dolan MA, Fein JA. Pediatric and adolescent mental health emergencies in the emergency medical services system. *Pediatrics*. 2011;127(5):e1356-66.
20. Newton AS, Hartling L, Soleimani A, Kirkland S, Dyson MP, Cappelli M. A systematic review of management strategies for children's mental health care in the emergency department: update on evidence and recommendations for clinical practice and research. *Emerg Med J*. 2017;34(6):376-84.
21. Horowitz LM, Bridge JA, Teach SJ, Ballard E, Klima J, Rosenstein DL, et al. Ask Suicide-Screening Questions (ASQ): a brief instrument for the pediatric emergency department. *Arch Pediatr Adolesc Med*. 2012;166(12):1170-6.
22. Horowitz LM, Wharff EA, Mournet AM, Ross AM, McBee-Strayer S, He J-P, et al. Validation and Feasibility of the ASQ Among Pediatric Medical and Surgical Inpatients. *Hosp Pediatr*. 2020;10(9):750-7.
23. DeVlyder JE, Ryan TC, Cwik M, Wilson ME, Jay S, Nestadt PS, et al. Assessment of Selective and Universal Screening for Suicide Risk in a Pediatric Emergency Department. *JAMA Network Open*. 2019;2(10):e1914070-e.
24. Cappelli M, Gray C, Zemek R, Cloutier P, Kennedy A, Glennie E, et al. The HEADS-ED: a rapid mental health screening tool for pediatric patients in the emergency department. *Pediatrics*. 2012;130(2):e321-7.
25. York A, Kingsbury S. *The choice and partnership approach: a transformational service model*. United Kingdom: CAPA Publications; 2013.
26. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. *Med Care*. 2012;50(3):217-26.
27. Amirav I, Vandall-Walker V, Rasiyah J, Saunders L. Patient and Researcher Engagement in Health Research: A Parent's Perspective. *Pediatrics*. 2017;140(3).
28. Darnay K, Hawke LD, Chaim G, Henderson J. *INNOVATE Research: Youth Engagement Guidebook for Researchers*. Toronto, ON; 2019.
29. Hawke LD, Relihan J, Miller J, McCann E, Rong J, Darnay K, et al. Engaging youth in research planning, design and execution: Practical recommendations for researchers. *Health Expect*. 2018;21(6):944-9.
30. International Association of Public Participation. *The IAP2 public participation spectrum: IAP2; 2016* [Available from: <http://www.iap2.org.au/resources/public-participation-spectrum>].
31. Abelson J, Li K, Wilson G, Shields K, Schneider C, Boesveld S. Supporting quality public and patient engagement in health system organizations: development and usability testing of the Public and Patient Engagement Evaluation Tool. *Health Expect*. 2016;19(4):817-27.
32. Health Quality Ontario. *Health Quality Ontario: Creating and sustaining patient and family advisory councils: Guides for common challenges - Recruiting for diversity*. In: Ontario HQ, editor. Ontario: Health Quality Ontario; n.d.
33. Canadian Institute of Health Research (CIHR). *Ethics Guidance for Developing Partnerships with Patients and Researchers*. In: Office CE, editor. Ottawa: CIHR; 2020.
34. *SAGE Handbook of Mixed Methods in Social & Behavioral Research*. 2010 2021/04/18. Thousand Oaks, California: SAGE Publications, Inc. 2. Available from:

<https://methods.sagepub.com/book/sage-handbook-of-mixed-methods-social-behavioral-research-2e>.

35. Morse JM. Approaches to qualitative-quantitative methodological triangulation. *Nurs Res.* 1991;40(2):120-3.
36. Boivin A, L'Espérance A, Gauvin FP, Dumez V, Macaulay AC, Lehoux P, et al. Patient and public engagement in research and health system decision making: A systematic review of evaluation tools. *Health Expect.* 2018;21(6):1075-84.
37. Dukhanin V, Topazian R, DeCamp M. Metrics and Evaluation Tools for Patient Engagement in Healthcare Organization- and System-Level Decision-Making: A Systematic Review. *Int J Health Policy Manag.* 2018;7(10):889-903.
38. O'Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health services research. *Journal of Health Services Research & Policy.* 2008;13(2):92-8.
39. Boote J, Wong R, A. B. "Talking the talk or walking the walk?" a bibliometric review of the literature on public involvement in health research published between 1995 and 2009. *Health Expectations.* 2015;18(1):44-57.
40. Heffernan OS, Herzog TM, Schiralli JE, Hawke LD, Chaim G, Henderson JL. Implementation of a youth-adult partnership model in youth mental health systems research: Challenges and successes. *Health Expectations.* 2017;20(6):1183-8.
41. McMaster University FoHS, Public & Patient Engagement. Public and Patient Engagement Evaluation Tool (PPEET): McMaster University, Faculty of Health Sciences, Public & Patient Engagement.; 2018 [Available from: <https://ppe.mcmaster.ca>.
42. Julia Abelson AHASJB, Maria J. Evaluating Patient, Family and Public Engagement in Health Services Improvement and System Redesign. *Healthcare Quarterly.* 2018;21(Special Issue):31-7.
43. Corbin J, Strauss A. Basics of qualitative research: techniques and procedures for developing grounded theory. 3rd ed. Thousand Oaks, California 2008.
44. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377-81.
45. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative Research in Psychology.* 2006;3:77-101.

Checklist of items for the Good Reporting of A Mixed Methods Study (GRAMMS) guideline [1,2]

Mixed methods reporting within the protocol: Evaluation of Parent and Youth Experiences in Advisory Groups as part of a Mental Health Care Clinical Trial	
GRAMMS guideline	Reported on Page Number
1) Describes the justification for using a mixed methods approach to the research question	p. 6-11
2) Describes the design in terms of the purpose, priority and sequence of methods	p. 11
3) Describes each method in terms of sampling, data collection and analysis	p. 10-17
4) Describes the integration of the quantitative and qualitative components	N/A at the protocol stage
5) Describes any limitation of one method associated with the presence of the other method	p. 5 – overall strengths and limitations
6) Describes any insights gained from mixing or integrating methods	N/A at the protocol stage

GRAMMS Good Reporting of A Mixed Methods Study

Reference:

1. O’Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health services research. *J Health Serv Res Policy*. 2008;13:92-98.

Guidance for Reporting Involvement of Patients and the Public (GRIPP2) Short Form [1]

Involvement of Patients and the Public reporting within the protocol: Evaluation of Parent and Youth Experiences in Advisory Groups as part of a Mental Health Care Clinical Trial		
Section	Topic Item	Reported on Page Number
1. Aim	Report the aim of patient and public involvement (PPI) in the study	p. 8-10
2. Methods	Provide a clear description of the methods used for PPI in the study	p. 11-15
3. Study results	Outcomes - Report the results of PPI in the study, including both positive and negative outcomes	N/A at protocol stage
4. Discussion and conclusions	Outcomes - Comment on the extent to which PPI influenced the study overall. Describe positive and negative effects	N/A at protocol stage
5. Reflections or critical perspective	Comment critically on the study, reflecting on the things that went well and those that did not, so others can learn from this experience	N/A at protocol stage

Reference:

1. Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research BMJ 2017; 358 :j3453 doi:10.1136/bmj.j3453

BMJ Open

Evaluation of Parent and Youth Experiences in Advisory Groups as part of a Mental Health Care Clinical Trial: Protocol for a Mixed Method Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059689.R1
Article Type:	Protocol
Date Submitted by the Author:	11-Apr-2022
Complete List of Authors:	<p>Rasiah, Jananee; Athabasca University Faculty of Health Disciplines, ; University of Alberta, Freedman, Stephen; University of Calgary, Departments of Pediatrics, Emergency Medicine and Community Health Sciences; The Hospital for Sick Children, Pediatrics Macdonald, Lee ; Alberta Health Services, Planning and Performance Prisnie, Kassi; University of Calgary Cumming School of Medicine, Pediatrics Eltorki, Mohamed; McMaster University Faculty of Health Sciences, Pediatrics Finkelstein, Yaron; University of Alberta, Department of Medicine; University of Alberta, Department of Pediatrics Hopkin, Gareth ; Institute of Health Economics Santana, Maria-Jose; University of Calgary, Community Health Sciences Thull-Freedman, Jennifer ; University of Calgary Cumming School of Medicine, Departments of Pediatrics and Emergency Medicine Stang, Antonia; University of Calgary, Pediatrics; Alberta Children's Hospital, Pediatrics Prebeg, Matthew; Centre for Addiction and Mental Health, Gagnon, Isabelle; McGill University, School of Physical and Occupational Therapy; Montreal Children's Hospital of the McGill University Health Center, Trauma Steele, Margaret; Memorial University of Newfoundland, Discipline of Psychiatry, Faculty of Medicine Mater, Ahmed; University of Saskatchewan, Pediatrics Katz, Laurence; University of Manitoba, Department of Psychiatry, Rady Faculty of Health Sciences Greenfield, Brian; McGill University, Psychiatry Plotnick, Laurie; McGill University, Pediatrics Monga, Suneeta; The Hospital for Sick Children, Dept. of Psychiatry Lipman, Ellen; McMaster University, Psychiatry and Behavioural Neurosciences Wright, Bruce; University of Alberta Faculty of Medicine and Dentistry, Pediatrics; Alberta Health Services, Stollery Children's Hospital Dimitropoulos, Gina; University of Calgary, Porter, Robert; Memorial University of Newfoundland, Pediatrics, Faculty of Medicine Hurley, Katrina; Dalhousie University Faculty of Medicine, Emergency Medicine</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Al Hamarneh, Yazid; University of Alberta, Medicine Newton, Amanda; University of Alberta,
Primary Subject Heading :	Emergency medicine
Secondary Subject Heading :	Mental health, Paediatrics
Keywords :	HEALTH SERVICES ADMINISTRATION & MANAGEMENT, MENTAL HEALTH, ACCIDENT & EMERGENCY MEDICINE



1
2
3 **Title: Evaluation of Parent and Youth Experiences in Advisory Groups as part of a Mental**
4 **Health Care Clinical Trial: Protocol for a Mixed Method Study**
5
6
7
8
9

10 **Authors**

11
12 Jananee Rasiah
13 jrasiah@athabascau.ca (corresponding author)
14 Athabasca University, Faculty of Health Disciplines, Athabasca, AB
15
16

17 Stephen B. Freedman
18 stephen.freedman@albertahealthservices.ca
19 University of Calgary, Departments of Pediatrics,
20 Emergency Medicine and Community Health Sciences, Calgary, AB
21
22

23 Lee Macdonald
24 Lee.Macdonald@albertahealthservices.ca
25 Alberta Health Services, Planning and Performance, Calgary, AB
26
27

28 Kassi Prisnie
29 Kassi.Prisnie@albertahealthservices.ca
30 University of Calgary Cumming School of Medicine, Pediatrics, Calgary, AB
31
32

33 Mohamed Eltorki
34 eltorkim@mcmaster.ca
35 McMaster University, Faculty of Health Sciences
36 Department of Pediatrics, Division of Pediatric Emergency Medicine, Hamilton, ON
37
38

39 Yaron Finkelstein, MD,
40 Yaron.Finkelstein@sickkids.ca
41 Divisions of Emergency Medicine and Clinical Pharmacology and Toxicology,
42 Hospital for Sick Children, University of Toronto, Toronto, ON
43
44

45 Gareth Hopkin
46 gareth.hopkin@wales.nhs.uk
47 Institute of Health Economics, Edmonton, AB
48 Velindre University NHS Trust, Cardiff, Wales
49
50

51 Maria J. Santana
52 mjsantan@ucalgary.ca
53 University of Calgary, University of Calgary, Community Health Sciences, Calgary, AB
54
55
56
57
58
59
60

1
2
3 Jennifer Thull-Freedman
4 Jennifer.thull-freedman@ahs.ca
5 University of Calgary Cumming School of Medicine, Departments of Pediatrics and Emergency
6 Medicine, Calgary, AB
7

8
9 Antonia S. Stang
10 Antonia.Stang@albertahealthservices.ca
11 Departments of Pediatrics, Emergency Medicine and Community Health Sciences,
12 University of Calgary, Calgary, AB
13

14
15 Matthew Prebeg (CAMH)
16 matthew.prebeg@camh.ca
17 Centre for Addiction and Mental Health, Toronto ON
18

19
20 Isabelle Gagnon
21 Isabelle.gagnon8@mcgill.ca
22 School of Physical & Occupational Therapy and Department of Pediatrics, Faculty of Medicine
23 and Health Sciences, McGill University, Montreal, QC
24

25
26 Margaret Steele
27 DeanofMedicine@med.mun.ca
28 Discipline of Psychiatry, Faculty of Medicine, Memorial University of Newfoundland,
29 St. John's NL
30

31
32 Ahmed Mater
33 mater999@me.com
34 College of Medicine, University of Saskatchewan, Saskatoon, SK
35

36
37 Laurence Katz
38 LKatz@hsc.mb.ca
39 Department of Psychiatry, Rady Faculty of Health Sciences, Winnipeg, MB
40

41
42 Brian Greenfield
43 briangreenfield13@gmail.com
44 Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, QC
45

46
47 Laurie H. Plotnick
48 laurie.plotnick@mcgill.ca
49 Department of Pediatrics, Faculty of Medicine and Health Sciences, McGill University,
50 Montreal, QC
51

52
53 Suneeta Monga
54 suneeta.monga@sickkids.ca
55 Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, ON
56
57
58
59
60

1
2
3
4 Ellen Lipman
5 lipmane@mcmaster.ca
6 Department of Psychiatry and Behavioural Neurosciences, Faculty of Health Sciences,
7 McMaster University, Hamilton, ON
8
9

10 Bruce Wright
11 bruce.wright2@albertahealthservices.ca
12 Department of Pediatrics, Faculty of Medicine and Dentistry,
13 University of Alberta, Edmonton, AB
14

15
16 Gina Dimitropoulos
17 gdimit@ucalgary.ca
18 Faculty of Social Work, University of Calgary, Calgary, AB
19

20 Robert Porter
21 bobsterpot@gmail.com
22 Discipline of Pediatrics, Faculty of Medicine, Memorial University of Newfoundland, St. John's
23 NL
24
25

26 Katrina Hurley
27 Katrina.Hurley@iwbk.nshealth.ca
28 Division of Pediatric Emergency Medicine, Department of Emergency Medicine, Faculty of
29 Medicine, Dalhousie University, Halifax, NS
30

31
32 Yazid Al Hamarneh
33 Scientific Officer, EPICORE Centre, Department of Medicine, University of Alberta, Edmonton,
34 AB
35

36 Amanda S. Newton
37 mandi.newton@ualberta.ca
38 Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton,
39 AB
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Patient engagement in health care research is a necessity to ensure that research objectives align with priorities, outcomes, and needs of the population under study, and to facilitate ease of implementation and adoption of findings. In clinical trials, there is an increasing focus on patient engagement during the planning and conduct of clinical trials due to the potential for ethical and methodological benefits. As patient engagement in clinical trials increases, there is a need to evaluate the approaches of these activities to contribute evidence on what is most appropriate and successful. The purpose of this study is to evaluate patient engagement processes and the activities of patient partners during and after a pediatric mental health care trial.

Methods and analysis: Using a mixed-methods study design, we will evaluate patient partners' engagement activities across set time points during the trial and after trial completion. In this study, the term "patient partner" is inclusive of two groups of people with lived experience: (1) caregivers (parents, formal/informal caregivers, and family), and (2) youth (ages 15-24 years). Engagement will be measured using the participant and project questionnaires of the Public and Patient Engagement Evaluation Tool (PPEET), followed sequentially by semi-structured interviews. Quantitative data from the PPEET questionnaire will be analyzed and reported using descriptive statistics. Data from open-ended questions from the PPEET questionnaires and semi-structured interviews will be analyzed using thematic analysis.

Ethics and dissemination: Approval from Athabasca University Research Ethics Board will be obtained for this project. Findings will be disseminated at both academic and public venues in-person and online using platforms that are caregiver and youth friendly.

Strengths and limitations of this study

- Validated evaluation tool used to measure outcomes of patient engagement across a pediatric mental health care trial
- Semi-structured interviews to elicit patient engagement experience
- Dedicated resources for patient engagement from concept to end-of-grant knowledge translation activities
- Limitation includes the ability to sustain parent and youth engagement over the course of the trial

Introduction

Within the last decade, research funding organizations in the United Kingdom, United States, Canada, Australia, and New Zealand have required that patient engagement be an integral part of the design, conduct, dissemination, and implementation of findings emerging from social and health care research (1-5). Patient engagement occurs when patients become partners through meaningful and active collaboration across the research process (2, 6). A recent systematic review has reported ethical, methodological, and study quality benefits from engaging patients as partners in health research (6). These benefits have also been demonstrated through youth engagement in research, in particular, in the areas of health promotion (7), mental health (8, 9), chronic pain (10), and community development (11). Steps taken to recognize youths' expertise within engagement practices in research are equally beneficial and include (i) ensuring a youth friendly approach (e.g., listening to what youth have to say and asking questions in a non-judgemental manner); (ii) recognizing diversity among youth (e.g., recruiting youth from different developmental stages and with varied sociodemographic characteristics); (iii) formalizing recognition of contributions that are authentic for youth (e.g., providing compensation for engagement, writing references for school/university/jobs, offering co-authorship on findings, or providing certificates of achievement); and (iv) establishing youth-friendly environments (e.g., creating respectful and welcoming spaces for ongoing communication among youth, adult researchers, and adult patient partners whether virtual or in-person and ensuring supports for youth who may find research topics to be potentially triggering) (12). When youth have been engaged in research with these practical recommendations in place, the experiences are youth-friendly and the results are more likely to be implemented and adopted widely (12-14).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

There is the emerging evidence around the benefits to engage patients as partners in clinical trials aimed to evaluate non-pharmacological or pharmacological interventions (15-18). These benefits include: (i) more appropriate and sensitive/ethical research designs; (ii) more appropriate wording and timing of administration of research instruments and interventions; (iii) improved readability and accessibility of research materials (*ethical benefits*); (iv) more patient and/or caregiver relevant research outcomes or endpoints (*methodological benefits*); (v) improved recruitment, retention, diversity, and trial experience/satisfaction of study participants; (vi) better adherence to the trial protocol; and (vii) faster study completion (*study quality benefits*) (18). Given this evidence, we saw the benefits of prioritizing engagement with patients as partners with lived experience comprised of youth and caregivers (defined in more detail below) across the lifespan of our pediatric mental health care trial.

Overview: Mental Health Care Pediatric Clinical Trial

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Trial development began in 2018, when members of our research team alongside a group of patients, families, and health care providers identified the need to make improvements to pediatric mental health care in emergency departments (EDs) (19). This group recognized EDs as a vital clinical care setting for children and youth experiencing acute mental health or substance misuse crises (20). Such crises were acknowledged to be stressful and overwhelming, leaving the youth and family vulnerable in the absence of appropriate care. The team reinforced the position that ED-based care should be: (1) family centred and multidisciplinary, (2) informed by evidence-based approaches that identify risk, inform ED care and disposition decision-making, and (3) consider family needs and preferences (20, 21). In response to this position, a novel ‘bundle’ of mental health care was created with feedback from patient partners (comprised of separate groups of youth and parent/caregivers). The bundle components were discussed and

1
2
3 prioritized through several in-person meetings and teleconferences that took place between 2017-
4
5 2019 (22). Patient partners also prioritized study outcomes and selected outcome measures that
6
7 were most relevant for self-reporting in mental health, satisfaction with care, and family
8
9 functioning. The results of this engagement were applied to both this trial as well as quasi-
10
11 experimental study that provided pilot data to inform the trial (22). The bundle combines three
12
13 evidence-based approaches to ED care, as follows:
14
15

- 16
17 1. Ask Suicide-Screening Questions (ASQ) to identify suicide risk at ED triage and to facilitate
18
19 faster access to appropriate treatment pathways (23-25);
20
21
- 22
23 2. HEADS-ED, a clinical mnemonic (Home, Education, Activities/peers, Drug/alcohol,
24
25 Suicidality, Emotions and behaviour, Discharge Resources), for a focused mental health
26
27 psychosocial evaluation to guide ED care and disposition decision-making (21, 26); and
28
29
- 30
31 3. A 'Choice' appointment post-ED care, in accordance with the Choice And Partnership
32
33 Approach (CAPA) to care. This is a family-centred approach to mental health service
34
35 organization (27), and its use recognizes the value of connecting children and youth to
36
37 follow-up services after a crisis.

38
39 The bundle will be evaluated using a type 1 comparative effectiveness-implementation
40
41 hybrid design (28). A cluster randomized trial will evaluate the effectiveness of the bundle
42
43 compared to current standards of ED mental health care, while bundle implementation will be
44
45 evaluated using multi-methods to better understand barriers and facilitators to the adoption in ED
46
47 care. The trial will take place in eight pediatric EDs across Canada in partnership with Pediatric
48
49 Emergency Research Canada (PERC), a national research network. The Conjoint Health
50
51 Research Ethics Board (CHREB), University of Calgary approved this study effective January 4,
52
53 2021 (Reference ID: REB20-1825). This trial was registered at clinicaltrials.gov (Identifier:
54
55
56
57
58
59
60

1
2
3 NCT04902391) with an estimated start date of November 1, 2021 and completion date of August
4
5 1, 2025. The protocol for this trial was submitted elsewhere for publication (see Appendix A for
6
7 trial timeline).
8
9

10 A patient engagement plan was created for the trial that was informed by principles of
11 patient engagement from many sources, including those specific to youth and caregivers (2, 12,
12 29-32). The plan will be evaluated in a trial sub-study, which is described below under patient
13 engagement evaluation study. The purpose of the patient engagement evaluation study is two-
14 fold: (1) evaluate the engagement of youth and caregivers in the trial design, conduct, outcomes
15 (and knowledge translation of outcomes) of the trial and (2) obtain research team members'
16 perspectives on the impact of patient engagement on all stages of the trial.
17
18
19
20
21
22
23
24
25

26 **Patient and Public Involvement**

27
28 The study protocol was conceptualized by JR (lead for patient engagement evaluation
29 study) with support from ASN (co-principal investigator of the primary mental health care
30 pediatric trial). LM (caregiver lead) and MP (youth lead) with lived experience and extensive
31 experience in patient engagement reviewed and provided feedback on this study protocol.
32
33 According to the patient engagement plan described below, all caregiver and youth advisory
34 members, will be invited to provide feedback on both process and findings at different time-
35 points across the primary mental health care pediatric trial. Feedback by advisory group
36 members on both trial process and findings will be shared at the executive research team
37 meetings for discussion and deliberation. Post executive research team meetings, a brief written
38 report about how suggestions have been incorporated will be circulated to advisory group
39 members.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 For the patient engagement evaluation study described below, caregiver and youth
4 advisory group members will be invited to partake in the interpretation of the aggregate results,
5 editing, and preparation of the manuscript for publication. Caregiver and youth advisory group
6 members will be invited to contribute to the overall knowledge integration and dissemination
7 plan. Both patient partner contributors (LM and MP) met the ICMJE criteria for authorship and
8 as such we acknowledge their valuable contributions through coauthorship of this study protocol.
9 Engagement of patient partners has ensured further accuracy, readability, and relevance of this
10 protocol to the science and practice of patient engagement in pediatric clinical trials.
11
12
13
14
15
16
17
18
19
20
21

22 **Patient Engagement Plan**

23 **Overview**

24
25 The patient engagement plan has two foci: (i) consultation in trial planning, whereby
26 youth and caregivers had the opportunity as advisors to provide feedback on the trial design, and
27 (ii) partnership, whereby youth and caregivers will be partners alongside research team members
28 during trial conduct, with both groups actively involved in collaborating and leading trial related
29 activities. These foci align with the practices recommended by the Canadian Institute of Health
30 Research when developing partnerships between patients and researchers (33). We will use the
31 term ‘patient advisor’ to denote those who are involved in a one-time engagement activity versus
32 ‘patient partner’ who will provide feedback during patient engagement activities throughout the
33 lifespan of the trial.
34
35
36
37
38
39
40
41
42
43
44
45

46 **Participants and Recruitment**

47
48 We used a multi-pronged approach to recruit patient partners representing two groups of
49 people with lived experience: (1) caregivers (including parents from diverse family forms),
50 formal/informal caregivers, and family) and (2) youth (ages 15-24 years). We will specify the
51
52
53
54
55
56
57
58
59
60

1
2
3 group we refer to within the protocol for particular instances as needed, but otherwise we mean
4
5 both groups. Initial recruitment began in 2017 with youth and caregivers from two family
6
7 advisory councils for child and adolescent mental health services in Calgary and Edmonton,
8
9 Alberta, Canada invited to provide feedback and perspectives on bundle design, trial planning,
10
11 and grant submission. The participation of these advisors has concluded, with one partner staying
12
13 as a team member for the trial, since funded.
14
15

16
17 The next phase of recruitment will focus on the participation of youth in a Youth
18
19 Advisory Group and caregivers in a Caregiver Advisory Group; the groups will be active during
20
21 trial conduct and post-trial knowledge translation activities. During youth and caregiver
22
23 recruitment, we will prioritize equity, diversity, and inclusion-based practices in patient
24
25 engagement (34), and plan to recruit individuals from different demographic groups, based on
26
27 age, gender identity, cultural identity, disability, or education. We will set up two advisory
28
29 groups to minimize power differentials amongst youth and caregivers and foster a safe space
30
31 whereby all members are comfortable sharing their perspectives.
32
33

34
35 Youth engagement liaisons/coordinators from the Centre for Addiction and Mental
36
37 Health (<https://www.camh.ca/>) (led by MP) will assist with recruitment of youth to join the
38
39 Youth Advisory Group. Caregiver recruitment will be overseen by another team member (JL)
40
41 who will use convenience sampling to recruit individuals through organizations partnered with
42
43 the team (Canadian Mental Health Association, Translating Emergency Knowledge for Kids
44
45 [TREKK], Children's Healthcare Canada).
46
47
48

49
50 Youth and caregivers who indicate interest in participating will be invited to attend a
51
52 virtual introductory meeting (one for youth; one for caregivers) with the trial co-leads (SBF and
53
54 ASN) and patient engagement leads (JR, MP, and LM). The meeting will provide an opportunity
55
56
57
58
59
60

1
2
3 for individuals to learn about the trial and the goal of patient partner engagement. Those
4
5 interested in joining the team as advisory group members will be asked to contact the trial's
6
7 patient engagement evaluation study lead (JR) and youth engagement lead (MP) to further
8
9 discuss and confirm their interest. Informed consent will be obtained at that time. Patient partners
10
11 can voluntarily revoke consent at any time during the course of the trial. Patient partners will be
12
13 supported by the patient engagement leads throughout the course of the project, as described
14
15 further under advisory group activities. The goal is to have membership in both advisory groups
16
17 filled between November 2021 and January 2022; the trial begins February 2022.
18
19
20
21

22 **Sample Size**

23
24 We could not find evidence in the literature to support best practice for optimal group
25
26 size for patient engagement in research. Therefore, we will exercise pragmatic considerations
27
28 and recommendations from team members and project liaisons with extensive experience
29
30 working in patient engagement. In particular, the size of the group should foster meaningful
31
32 engagement, so that we are able to have robust discussion, and patient partners can share ideas in
33
34 a safe space. Conversely, we do not want a group too large that it is ineffective to engage
35
36 partners in discussions. We anticipate a target size of five to ten patient partners per advisory
37
38 group will be sufficient to lead to a meaningful discussion.
39
40
41

42 Patient partners that do not continue for the full duration of planned patient engagement
43
44 activities will be included in the sample if they are willing. Patient partners who attend the
45
46 virtual introductory meeting with the study co-lead, but later decline to participate in an advisory
47
48 group will be asked if they are willing to share confidentially the reasons that led to the decision
49
50 to forego participation. If we have attrition of advisory group members at any stage of the
51
52
53
54
55
56
57
58
59
60

1
2
3 engagement process, we want to have the opportunity to formally document their reasons that led
4
5 to that decision as part of the evaluation of patient engagement.
6

7 **Advisory Group Activities**

8
9
10 Advisory groups will be co-chaired by (MP, LM, and JR). At the first meeting of each
11
12 group, members will discuss group norms, establish terms of reference for the respective
13
14 advisory groups, including role description and individual goals as they relate to the patient
15
16 engagement activities. Meetings will occur at least four times/year for up to three years, which is
17
18 aligned with key milestones within the trial (see Appendix B). Compensation will be provided at
19
20 a set annual rate per year that was budgeted in the grant. Institutionally approved
21
22 videoconferencing platforms will be used to exchange and share information about the study.
23
24 Patient partners will have the ability to choose the types of engagement activities that they would
25
26 like to participate in, and this will be determined on an individual and/or advisory group basis.
27
28 These activities include co-leading the advisory group alongside the chairs, providing feedback
29
30 on recruitment materials for the trial and telephone scripts used during data collection with trial
31
32 participants, informing changes to recruitment and retention processes during trial conduct,
33
34 providing impressions on the results, and designing/preparing materials to disseminate trial
35
36 results (e.g., statements for social media use, infographics for families). Patient partners will also
37
38 have the opportunity to apply for funding to attend conferences and courses related to children's
39
40 mental health (budgeted within the trial) and/or work with the patient engagement evaluation
41
42 study lead (JR) to plan and conduct evaluation meetings.
43
44
45
46
47
48

49 **Patient Engagement Evaluation Study**

50 **Design**

51
52
53
54
55
56
57
58
59
60

1
2
3 We are using a mixed-method design to evaluate the trial's patient engagement plan (35,
4 36). In particular, we chose the exploratory sequential mixed method design because we will first
5 complete data collection and analyses using quantitative methods followed by qualitative
6 methods (37). This will involve surveying patient advisors and partners as well as research team
7 members on engagement experiences followed by semi-structured interviews of patient partners
8 to gather more detailed information on engagement experiences and activities highlighted in
9 survey responses. In addition, we will place equal weighting on both quantitative and qualitative
10 methods (37) because our research purpose is to evaluate engagement and determine impact of
11 that engagement to the pediatric mental health care trial. Thus, to do that effectively, we
12 emphasize that the data collected and analyzed using both methods will address the two-fold
13 purpose. We will use the Good Reporting of Mixed Method Study Criteria (38) and the Guidance
14 for Reporting Involvement of Patients and the Public (GRIPP2) (39) to assess the quality of
15 reporting of our mixed method patient engagement evaluation study procedures and findings.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Framework for Measuring Patient Engagement**

34

35 We are using a framework to guide outcome measurement. This framework contains four
36 domains—integrity of design and process; flexibility; mentorship; influence and impact—and
37 was adapted from the published literature on patient and youth engagement (32), (40). Integrity
38 of design and process will be assessed by examining advisory group representation (e.g., Do
39 members represent different experiences based on age, gender identity, cultural identity,
40 disability, or education?) and how group members are supported in patient engagement activities
41 (e.g., Are members compensated for their involvement in activities? Is information produced at an
42 appropriate education level for members?) (32). Flexibility of advisory groups with caregivers
43 and youth will be assessed by examining the terms of reference (role, structure, norms, and
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 frequency of interactions) of the groups and how those terms of reference are carried out across
4 the research project (40). Mentorship will be assessed by asking patient partners about advisory
5 group trial activities and opportunities that aligned with personal goals (40). Influence and
6 impact will be assessed by examining whether patient engagement activities informed or
7 changed trial decisions (32).
8
9

14 **Measurement of Patient Engagement**

16 **Public and Patient Engagement Evaluation Tool**

17
18 We will use the Public and Patient Engagement Evaluation Tool (PPEET) to measure
19 patient engagement across our domains of interest: integrity of design and process, flexibility,
20 mentorship, and influence and impact. The PPEET is comprised of two questionnaires which
21 will allow us to evaluate perspectives and experiences of advisory group members (participant
22 questionnaire) and research team members (project questionnaire). The participant questionnaire
23 also contains questions to measure one-time and ongoing patient engagement experiences, which
24 will ensure that patient partners with different experiences contribute to the evaluation. At this
25 time, we are aware of at least twenty-seven tools to evaluate patient and public engagement (1,
26 41, 42). We chose the PPEET because it was used to evaluate patient and public engagement
27 within the context of health research. The PPEET was highly rated by the Centre of Excellence
28 on Partnership with Patients and the Public (CEPPP) because of high scores in the domains of
29 scientific rigour, patient and public perspective, comprehensiveness, and usability (1, 41, 42).
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 In Table 1, we outline how our domains of interest will be measured using the PPEET
48 participant and project questionnaires. We also identify time-points of when each questionnaire
49 will be administered. Advisory group members will also be asked to fill out a six-item
50 demographic questionnaire, as part of the PPEET, to provide to allow us to measure
51
52
53
54
55
56
57
58
59
60

1
2
3 representation as part of integrity of design and process. The questions include year of birth, sex,
4
5 group of people or communities one identifies with, highest level of education completed,
6
7 current work status, and paid experience in a health care profession. Additionally, we will
8
9 include a description about advisory members' previous experience with patient engagement in
10
11 research (information will be obtained when we recruit members).
12
13

14 **PPEET Participant Questionnaire**

15
16 The one-time engagement questionnaire is comprised of 19 questions: 13 questions based
17
18 on a five-point Likert scale (range: strongly disagree to strongly agree) and six open-ended
19
20 questions. The questionnaire will be administered to each patient advisor immediately after the
21
22 conclusion of an engagement activity. The on-going engagement questionnaire will be
23
24 administered to patient partners every three to six months during trial conduct. This
25
26 questionnaire is comprised of a total of 20 questions: 14 questions based on a five-point Likert
27
28 scale (range: strongly disagree to strongly agree) and six open-ended questions.
29
30
31

32 **PPEET Project Questionnaire**

33
34 We will use the PPEET three-module project questionnaire to assess involvement in
35
36 patient engagement among the principal investigators, project manager, implementation site
37
38 leads, and youth engagement liaisons/coordinators. The first module (Module A) consists of 12
39
40 questions on a five-point Likert scale (range: strongly disagree to strongly agree) and three open-
41
42 ended questions to assess how and whether study team members have chosen appropriate patient
43
44 engagement activities during the planning stage. This module will be administered prior to trial
45
46 conduct and after the run-in period. The second module (Module B) identifies how well patient
47
48 engagement activities were executed (10 five-point Likert questions; six open-ended questions)
49
50 and will be administered after the trial engagement activities are completed. The third module
51
52
53
54
55
56
57
58
59
60

(Module C) will evaluate the impact of patient engagement activities. This module includes four questions (five-point Likert scale; range: strongly disagree to strongly agree) and four open-ended questions, that will be administered three to six months after the completion of the engagement activities.

Semi-Structured Interviews

We will interview patient partners at the end of the trial after the completion of all engagement activities. Interview questions will be developed based on the themes that emerge from the open-ended responses collected at different time-point using the PPEET with the intent to gather more information on engagement experiences and activities (43). Patient partners will be offered the choice to participate in individual or focus group interviews that will be conducted by a research nurse/graduate student. Focus group interviews will be held separately for youth and caregivers. A final forum inviting all patient partners and research team members to attend will be held to discuss and obtain feedback on synthesized questionnaire results and interview findings.

Additional Data Sources: Supporting Documents and Trial Protocol Documents

Supporting documents for the pediatric mental health care trial such as meeting agendas, minutes, or tailored resources for advisory group members will be reviewed monthly and will serve as additional data sources to understand patient engagement activities. Trial protocol documents will be collected annually from the trial research coordinator to determine how feedback from advisory group members were used to inform/modify trial decisions.

Data Collection and Management

We will administer the PPEET online using the Research Electronic Data Capture (REDCap©) tools (44) hosted and supported by the Women and Children's Health Research

Institute at the University of Alberta. Data collected through this platform by a research nurse/graduate student will be de-identified and will not be tracked to any individual participant. In exceptional cases, such as limited participant access to online environments, the PPEET will be administered via telephone with answers entered by the interviewer into the REDCap© database. Data will be stored in REDCap© until exported for analysis.

Semi-structured interviews will be conducted via telephone/video-conferencing platform hosted by the University of Calgary (Zoom©) and the audio will be recorded. Interview recordings will be transcribed verbatim, checked for accuracy against the original recordings, and identifiers will be removed from the transcripts to maintain confidentiality. Data from the semi-structured interviews and the audio recordings will be stored securely in a server at the University of Alberta until the data are transcribed and subsequently analyzed.

Field notes will be kept when additional data sources are reviewed. Supporting documents will be reviewed during regular advisory group meetings to keep informed of the trial progress. Trial protocol documents will be collected and reviewed annually from the trial research coordinator to note modifications that have been implemented across sites based on advisory group members' feedback.

Table 1. Overview of the approach to measuring patient engagement.

Integrity of design and process; Flexibility; Mentorship		
PPEET questionnaire	Questionnaire outcomes	Administration time-point
Participant Questionnaire: One-time engagement activities (Module A – Parts A and B)	<ul style="list-style-type: none"> Advisory group members represent diverse range of views Advisory group members are provided supports that enable participation in engagement activities 	At the end of the activity on the same day
Participant Questionnaire: Ongoing engagement activities (Module B – Parts A and B)		Between 3-6 months
Project Questionnaire (Module A – Parts A, B, and C)	<ul style="list-style-type: none"> Online platforms suitable for communication with patient partners Clear and bi-directional communication achieved among 	Pre-trial conduct (pre-recruitment of trial participants)

	<p>patient partners and researchers</p> <ul style="list-style-type: none"> • Mentorship opportunities created and tailored to patient partners' interests 	
Influence and impact		
Participant Questionnaire: One-time engagement activities (Module A – Parts C and D)	<ul style="list-style-type: none"> • Engagement activities inform planning and/or decision making in the trial • Engagement activities improve patient partners' knowledge of mental health and substance use crises in emergency departments • Engagement activities improve patient partners' knowledge of the patient and family-centred acute mental health care bundle and need for implementation • Increased confidence and trust of patient partners in members of the team 	At the end of the activity on the same day
Participant Questionnaire: Ongoing engagement activities (Module B – Parts C and D)	<ul style="list-style-type: none"> • Increased confidence of patient partners in the study purpose • Increased confidence of patient partners in the impact of bundle implementation on mental health 	Between 3-6 months
Project Questionnaire (Module B – Parts A, B, and C)	<ul style="list-style-type: none"> • Clinicians, staff, and researchers improve knowledge on patient partners' perspectives about the bundle 	Post-activity
Project Questionnaire (Module C – Parts A, B, and C)		3-6 months after engagement has concluded

Data Analysis

Data from the PPEET will be entered into SPSS© Version 27. We will use descriptive statistics (e.g., means and standard deviations, medians with interquartile range) to report group characteristics and responses to the Likert scale questions. Frequency and percentages will be reported for categorical information. Data from open-ended questions (45) and semi-structured interviews will be imported into NVIVO © Version 12. We will undertake thematic analysis (45) to analyze these data. Data from open-ended questions will be grouped by question and then coded for common themes that arise across the data. The primary coder (research nurse or

graduate student) and first author (JR) will meet at least three times during the development and application of the coding scheme as part of an iterative process to ensure coding reliability. Coding reliability by the study co-lead (ASN) will be completed to resolve inconsistencies or disputes and to review independent coding of selected data excerpts.

Data from semi-structured interviews will be analyzed using the coding scheme as a guide. Data that cannot be coded to existing codes or themes will be noted. In the later stages of analysis, the study co-lead (ASN) will independently code data excerpts to maintain coding reliability. Advisory group members' feedback on supporting documents and trial protocol documents will be reviewed and synthesized into field notes by a research nurse and research assistant, which will be reported as a narrative.

Ethics and Dissemination

Ethical approval for this study was obtained through the Athabasca University Research Ethics Board (file no: 24575) for one year and is subject for renewal on an annual basis since the project is ongoing beyond one year. All participating advisory group members will receive an information sheet that will provide details on the purpose of the study, identify the potential risks/benefits, and explain the voluntary nature of their participation. Patient advisors and partners can revoke consent from participating in the parent or youth advisory group and evaluation activities at any time. Patient advisors and partners may choose to omit particular questions while filling out the survey or during the interview (pertains only to patient partners). All data will be de-identified; therefore, individual participant data cannot be removed once collected. Data will be kept confidential. All data will be stored using secured software on a password-protected server and device.

1
2
3 Patient engagement evaluation findings will be shared with parent and youth advisory
4 group members during virtual meetings. Advisory group members will be asked about how the
5 results fit within the organizing framework and whether the patient engagement outcomes were
6 met. Dissemination of findings from this patient engagement evaluation study for the pediatric
7 mental health care trial will be in the form of an academic publication in a reputable peer-
8 reviewed journal, presentations at TREKK and PERC conferences/meetings, public presentations
9 at appropriate venues, and as posts or blogs on the research study website and online platforms
10 that are parent and youth friendly. Research team members and advisory group members will be
11 invited to co-author, co-develop, and co-present these findings targeted at multiple venues.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributorship statement:

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

The study protocol was conceptualized by JR (lead for patient engagement sub-study) with support from ASN (co-principal investigator of the primary mental health care pediatric trial). LM (caregiver lead) and MP (youth lead) with lived experience reviewed and provided feedback on this study protocol. SBF (co-principal investigator of the primary mental health care pediatric trial) critically reviewed the manuscript while considering the pediatric trial timeline. KP was instrumental in creating the first draft of the patient engagement plan and obtaining feedback about the patient engagement activities from patient partners. ME, YF, GH, M-JS, J-TF, ASS, IG, MS, AM, LK, BG, LHP, SM, ELL, BW, GD, RP, KH, and YNAH reviewed the manuscript and provided feedback on feasibility and timing of the patient engagement activities and planned evaluation methods.

Competing interests: None declared.

Funding: This trial is funded by the Canadian Institutes of Health Research (CIHR) as a Strategy for Patient-Oriented Research (SPOR) Innovative Clinical Trial Multi-Year Grant (Funding reference number: MYG – 171686).

Data sharing statement: No, do not send my information to Dryad.

Ethics ID: Athabasca University Research Ethics Board review was approved effective November 25, 2021. Reference ID: 24575 (Project title: Evaluation of Parent and Youth Experiences in Advisory Groups as part of a Mental Health Care Clinical Trial: Protocol for a Mixed Method Study)

1
2
3
4 **Ethics ID for primary trial:** The Conjoint Health Research Ethics Board (CHREB), University
5 of Calgary review (Primary Site) was approved effective January 4, 2021. Reference ID: REB20-
6 1825 (Project title: A Multi-Disciplinary, Patient-Partnered, Pan-Canadian, Comparative
7 Effectiveness Evaluation of an Innovative Acute Pediatric Mental Health and Addiction Care
8 Bundle)
9

10
11 **Trial registration ID:** clinicaltrials.gov; ClinicalTrials.gov Identifier: NCT04902391
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Boivin A, Richards T, Forsythe L, Grégoire A, L'Espérance A, Abelson J, et al. Evaluating patient and public involvement in research. *BMJ*. 2018;363:k5147.
2. Canadian Institutes of Health Research. Strategy for Patient Oriented Research. Patient engagement framework Ottawa: CIHR; 2014 [Available from: http://www.cihr-irsc.gc.ca/e/documents/spor_framework-en.pdf].
3. Frank L, Forsythe L, Ellis L, Schrandt S, Sheridan S, Gerson J, et al. Conceptual and practical foundations of patient engagement in research at the patient-centered outcomes research institute. *Qual Life Res*. 2015;24(5):1033-41.
4. Saunders C, Crossing S, Girgis A, Butow P, Penman A. Operationalising a model framework for consumer and community participation in health and medical research. *Aust New Zealand Health Policy*. 2007;4:13.
5. Staley K. *Exploring Impact: Public involvement in NHS, public health and social care research*. Eastleigh; 2009.
6. McCarron TL, Clement F, Rasiah J, Moran C, Moffat K, Gonzalez A, et al. Patients as partners in health research: A scoping review. *Health Expect*. 2021.
7. Peréa FC, Sayles NR, Reich AJ, Koomas A, McMann H, Sprague Martinez LS. "Mejorando Nuestras Oportunidades": Engaging Urban Youth in Environmental Health Assessment and Advocacy to Improve Health and Outdoor Play Spaces. *Int J Environ Res Public Health*. 2019;16(4).
8. Bell E. Young Persons in Research: A Call for the Engagement of Youth in Mental Health Research. *Am J Bioeth*. 2015;15(11):28-30.
9. Mawn L, Welsh P, Stain HJ, Windebank P. Youth Speak: increasing engagement of young people in mental health research. *J Ment Health*. 2015;24(5):271-5.
10. Birnie KA, Dib K, Ouellette C, Dib MA, Nelson K, Pahtayken D, et al. Partnering For Pain: A Priority Setting Partnership to identify patient-oriented research priorities for pediatric chronic pain in Canada *CMAJ*. 2019;7(4):E654-E64
11. Battaglia TA, Pamphile J, Bak S, Spencer N, Gunn C. Connecting Community to Research: A Training Program to Increase Community Engagement in Research. *Prog Community Health Partnersh*. 2019;13(2):209-17.
12. Hawke LD, Relihan J, Miller J, McCann E, Rong J, Darnay K, et al. Engaging youth in research planning, design and execution: Practical recommendations for researchers. *Health Expect*. 2018;21(6):944-9.
13. Checkoway B, Richards-Schuster K. Youth Participation in Community Evaluation Research. *American Journal of Evaluation*. 2003;24(1):21-33.
14. Hawke LD, Darnay K, Relihan J, Khaleghi-Moghaddam M, Barbic S, Lachance L, et al. Enhancing researcher capacity to engage youth in research: Researchers' engagement experiences, barriers and capacity development priorities. *Health Expect*. 2020;23(3):584-92.
15. Bartlett SJ, Barnes T, McIvor RA. Integrating patients into meaningful real-world research. *Ann Am Thorac Soc*. 2014;11 Suppl 2:S112-7.
16. Domecq JP, Prutsky G, Elraiyah T, Wang Z, Nabhan M, Shippee N, et al. Patient engagement in research: a systematic review. *BMC Health Serv Res*. 2014;14:89.
17. Bagley HJ, Short H, Harman NL, Hickey HR, Gamble CL, Woolfall K, et al. A patient and public involvement (PPI) toolkit for meaningful and flexible involvement in clinical trials – a work in progress. *Research Involvement and Engagement*. 2016;2(1):15.

18. Vat LE, Finlay T, Jan Schuitmaker-Warnaar T, Fahy N, Robinson P, Boudes M, et al. Evaluating the "return on patient engagement initiatives" in medicines research and development: A literature review. *Health Expect*. 2020;23(1):5-18.
19. Bialy L, Plint AC, Freedman SB, Johnson DW, Curran JA, Stang AS, et al. Pediatric Emergency Research Canada (PERC): Patient/Family-informed Research Priorities for Pediatric Emergency Medicine. *Academy of Emergency Medicine*. 2018:1365-74.
20. Dolan MA, Fein JA. Pediatric and adolescent mental health emergencies in the emergency medical services system. *Pediatrics*. 2011;127(5):e1356-66.
21. Newton AS, Hartling L, Soleimani A, Kirkland S, Dyson MP, Cappelli M. A systematic review of management strategies for children's mental health care in the emergency department: update on evidence and recommendations for clinical practice and research. *Emerg Med J*. 2017;34(6):376-84.
22. Freedman S, Thull-Freedman J, Lightbody T, Prisnie K, Wright B, Coulombe A, et al. Introducing an innovative model of acute paediatric mental health and addictions care to paediatric emergency departments: a protocol for a multicentre prospective cohort study. *BMJ Open Quality*. 2020;9(4):e001106.
23. Horowitz LM, Bridge JA, Teach SJ, Ballard E, Klima J, Rosenstein DL, et al. Ask Suicide-Screening Questions (ASQ): a brief instrument for the pediatric emergency department. *Arch Pediatr Adolesc Med*. 2012;166(12):1170-6.
24. Horowitz LM, Wharff EA, Mournet AM, Ross AM, McBee-Strayer S, He J-P, et al. Validation and Feasibility of the ASQ Among Pediatric Medical and Surgical Inpatients. *Hosp Pediatr*. 2020;10(9):750-7.
25. DeVlyder JE, Ryan TC, Cwik M, Wilson ME, Jay S, Nestadt PS, et al. Assessment of Selective and Universal Screening for Suicide Risk in a Pediatric Emergency Department. *JAMA Network Open*. 2019;2(10):e1914070-e.
26. Cappelli M, Gray C, Zemek R, Cloutier P, Kennedy A, Glennie E, et al. The HEADS-ED: a rapid mental health screening tool for pediatric patients in the emergency department. *Pediatrics*. 2012;130(2):e321-7.
27. York A, Kingsbury S. The choice and partnership approach: a transformational service model. United Kingdom: CAPA Publications; 2013.
28. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. *Med Care*. 2012;50(3):217-26.
29. Amirav I, Vandall-Walker V, Rasiyah J, Saunders L. Patient and Researcher Engagement in Health Research: A Parent's Perspective. *Pediatrics*. 2017;140(3).
30. Darnay K, Hawke LD, Chaim G, Henderson J. INNOVATE Research: Youth Engagement Guidebook for Researchers. Toronto, ON; 2019.
31. International Association of Public Participation. The IAP2 public participation spectrum: IAP2; 2016 [Available from: <http://www.iap2.org.au/resources/public-participation-spectrum>].
32. Abelson J, Li K, Wilson G, Shields K, Schneider C, Boesveld S. Supporting quality public and patient engagement in health system organizations: development and usability testing of the Public and Patient Engagement Evaluation Tool. *Health Expect*. 2016;19(4):817-27.
33. Canadian Institute of Health Research (CIHR). Ethics Guidance for Developing Partnerships with Patients and Researchers. In: Office CE, editor. Ottawa: CIHR; 2020.

- 1
2
3 34. Health Quality Ontario. Health Quality Ontario: Creating and sustaining patient and
4 family advisory councils: Guides for common challenges - Recruiting for diversity. In: Ontario
5 HQ, editor. Ontario: Health Quality Ontario; n.d.
- 6 35. SAGE Handbook of Mixed Methods in Social & Behavioral Research. 2010
7 2021/04/18. Thousand Oaks, California: SAGE Publications, Inc. 2. Available from:
8 [https://methods.sagepub.com/book/sage-handbook-of-mixed-methods-social-behavioral-](https://methods.sagepub.com/book/sage-handbook-of-mixed-methods-social-behavioral-research-2e)
9 [research-2e](https://methods.sagepub.com/book/sage-handbook-of-mixed-methods-social-behavioral-research-2e).
- 10 36. Morse JM. Approaches to qualitative-quantitative methodological triangulation. *Nurs*
11 *Res.* 1991;40(2):120-3.
- 12 37. Creswell JW, Clark VLP. *Designing and conducting mixed methods research* 2007.
- 13 38. O' Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health
14 services research. *Journal of Health Services Research & Policy.* 2008;13(2):92-8.
- 15 39. Boote J, Wong R, A. B. "Talking the talk or walking the walk?" a bibliometric review of
16 the literature on public involvement in health research published between 1995 and 2009. *Health*
17 *Expectations.* 2015;18(1):44-57.
- 18 40. Heffernan OS, Herzog TM, Schiralli JE, Hawke LD, Chaim G, Henderson JL.
19 Implementation of a youth-adult partnership model in youth mental health systems research:
20 Challenges and successes. *Health Expectations.* 2017;20(6):1183-8.
- 21 41. Boivin A, L'Espérance A, Gauvin FP, Dumez V, Macaulay AC, Lehoux P, et al. Patient
22 and public engagement in research and health system decision making: A systematic review of
23 evaluation tools. *Health Expect.* 2018;21(6):1075-84.
- 24 42. Dukhanin V, Topazian R, DeCamp M. Metrics and Evaluation Tools for Patient
25 Engagement in Healthcare Organization- and System-Level Decision-Making: A Systematic
26 Review. *Int J Health Policy Manag.* 2018;7(10):889-903.
- 27 43. Corbin J, Strauss A. *Basics of qualitative research: techniques and procedures for*
28 *developing grounded theory.* 3rd ed. Thousand Oaks, California 2008.
- 29 44. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
30 data capture (REDCap)--a metadata-driven methodology and workflow process for providing
31 translational research informatics support. *J Biomed Inform.* 2009;42(2):377-81.
- 32 45. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative Research in*
33 *Psychology.* 2006;3:77-101.
- 34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix A: Pediatric Mental Health Care Trial

Y1		Y2				Y3				Y4				Y5			
2020		2021				2022				2023				2024			
Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Experimental Intervention Sites (N=4)																	
Preparation						Run-In	Bundle Implementation										Data Analysis
Control Intervention Sites (N=4)																	
Preparation						Run-In	Routine/existing approach to mental healthcare										Data Analysis

Y=: year; Q: quarter

Or peer review only

BMJ Open: first published as 10.1136/bmjopen-2021-059689 on 17 June 2022. Downloaded from <http://bmjopen.bmj.com/> on November 10, 2024 by guest. Protected by copyright.

Appendix B: Advisory Group Activities

Trial Milestones	Activities	Status	Year(Y)/Quarter (Q)
Bundle and protocol refinement	Feedback on bundle implementation and study survey	Completed	2018 (during grant application/submission stage)
Trial governance	Caregiver advisory group lead attends national team meetings	Ongoing	Y3:2022/Q1
	Establish lead for youth advisory group	Completed	Y2:2021/Q4
	Finalize contracts with CAMH	Completed	Y2:2021/Q4
	Two advisory groups established to inform trial activities: Youth advisory group (led by CAMH youth lead) and Caregiver advisory group (led by caregiver lead)	Recruitment & Onboarding of advisory group members	Y3:2022/Q1
Integrated knowledge translation	Co-create educational tools for youth, families, and/or health care providers on clinical care changes (intervention sites with info on bundle of care)	Not yet started	Y3:2022/Q1
	Co-create recruitment materials for the study	Not yet started	Y3:2022/Q1
	Co-create newsletter updates for social media; email; website about the study and seed grant calls	Not yet started	Y3:2022/Q2-Q4 Y4:2023/Q1-Q4 Y5:2024/Q1-Q4
Personal development	Seed grant to carry out a project(s) in acute mental healthcare and travel grant to attend meeting or conference	Not yet started	Y3:2022/Q1-Q4 Y4:2023/Q1-Q4
Supporting implementation	Input on trial activities including support in writing trial updates	Not yet started	Y3:2022/Q1-Q4 Y4:2023/Q1-Q4 Y5:2024/Q1-Q4
End-of-grant knowledge translation	Forum with all patient partners and research team members	Not yet started	Y5:2024/Q4
	Co-design 1-2-page bottom-line summaries targeting health care providers on	Not yet started	Y5:2024/Q4 Y6:2025/Q1

	acute mental healthcare recommendations		
	Development of scientific summaries	Not yet started	Y5:2024/Q4 Y6:2025/Q1
	Patient partners with interest in collaborating on manuscripts will be considered for authorship, and may have the opportunity to co-present findings and public and scientific forums/conferences	Not yet started	Y5:2024/Q4 Y6:2025/Q1

Checklist of items for the Good Reporting of A Mixed Methods Study (GRAMMS) guideline [1,2]

Mixed methods reporting within the protocol: Evaluation of Parent and Youth Experiences in Advisory Groups as part of a Mental Health Care Clinical Trial	
GRAMMS guideline	Reported on Page Number
1) Describes the justification for using a mixed methods approach to the research question	p. 6-11
2) Describes the design in terms of the purpose, priority and sequence of methods	p. 11
3) Describes each method in terms of sampling, data collection and analysis	p. 10-17
4) Describes the integration of the quantitative and qualitative components	p. 13
5) Describes any limitation of one method associated with the presence of the other method	p. 5 – overall strengths and limitations
6) Describes any insights gained from mixing or integrating methods	N/A at the protocol stage

GRAMMS Good Reporting of A Mixed Methods Study

Reference:

1. O’Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health services research. *J Health Serv Res Policy*. 2008;13:92-98.

Guidance for Reporting Involvement of Patients and the Public (GRIPP2) Short Form [1]

Involvement of Patients and the Public reporting within the protocol: Evaluation of Parent and Youth Experiences in Advisory Groups as part of a Mental Health Care Clinical Trial		
Section	Topic Item	Reported on Page Number
1. Aim	Report the aim of patient and public involvement (PPI) in the study	p. 8-10
2. Methods	Provide a clear description of the methods used for PPI in the study	p. 11-15
3. Study results	Outcomes - Report the results of PPI in the study, including both positive and negative outcomes	N/A at protocol stage
4. Discussion and conclusions	Outcomes - Comment on the extent to which PPI influenced the study overall. Describe positive and negative effects	N/A at protocol stage
5. Reflections or critical perspective	Comment critically on the study, reflecting on the things that went well and those that did not, so others can learn from this experience	N/A at protocol stage

Reference:

1. Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research BMJ 2017; 358 :j3453 doi:10.1136/bmj.j3453